Renovaro Biosciences Inc. (RENB )

Currency in USD Disclaimer
$0.27 -$0.02 (-5.85%)
Closed 07/01/2025
$0.27
$0.3
$0.27
$2.1

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol RENB
  • Company Renovaro Biosciences Inc.
  • Price $0.27
  • Changes Percentage -5.85
  • Change -0.0169
  • Day Low $0.27
  • Day High $0.3
  • Year High $2.1
  • Year Low $0.27
  • Market Cap $61,566,966
  • Price Avg 50 EMA (D) $0.34
  • Price Avg 200 EMA (D) $0.66
  • Exchange NASDAQ
  • Volume 867,753
  • Average Volume 3,241,380
  • Open $0.29
  • Previous Close $0.29
  • EPS -0.25
  • PE -1.43
  • Earnings Announcement 2025-05-15 20:00:00
  • Shares Outstanding $172,119,000

Company brief: RENOVARO BIOSCIENCES INC. (RENB )

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.

RENB Corporation News

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30, 2025 at 1:21 pm ET

accessnewswire.com -- LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed...

Income Statement